Resilient Pharmaceuticals
Lykos Therapeutics logo | |
| Formerly | Lykos Therapeutics; MAPS Public Benefit Corporation; MAPS PBC |
|---|---|
| Type | Public benefit corporation |
| Industry | Pharmaceutical; Psychedelic medicine |
| Founded | 2014 |
| Headquarters | |
| Website | lykospbc |
Resilient Pharmaceuticals, formerly known as Lykos Therapeutics and before that as the MAPS Public Benefit Corporation (MAPS PBC), is a public benefit corporation (PBC) developing MDMA ("ecstasy") for potential medicinal use. It was founded and is part-owned by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS PBC was founded in 2014 and was renamed to Lykos Therapeutics in January 2024, then to Resilient Pharmaceuticals in August 2025.